We are live on ! Find out more
ALXO icon

ALX Oncology

76 hedge funds and large institutions have $160M invested in ALX Oncology in 2023 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 23 increasing their positions, 22 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,557% more call options, than puts

Call options by funds: $1.01M | Put options by funds: $61K

20% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 10

1% more funds holding

Funds holding: 7576 (+1)

5% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 22

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

3.03% less ownership

Funds ownership: 83.91%80.88% (-3%)

38% less capital invested

Capital invested by funds: $258M → $160M (-$97.8M)

Holders
76
Holders Change
+1
Holders Change %
+1.33%
% of All Funds
1.21%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
12
Increased
23
Reduced
22
Closed
10
Calls
$1.01M
Puts
$61K
Net Calls
+$950K
Net Calls Change
+$297K
Name Holding Trade Value Shares
Change
Change in
Stake
NFSG
76
Newbridge Financial Services Group
Florida
$106
AG
77
Artal Group
Luxembourg
-$3.75M -500,000 Closed
Millennium Management
78
Millennium Management
New York
-$672K -123,933 Closed
HF
79
HRT Financial
New York
-$189K -25,176 Closed
GCP
80
GSA Capital Partners
United Kingdom
-$96K -12,730 Closed
UBS AM
81
UBS AM
Illinois
-$52.3K -11,581 Closed
MIM
82
MetLife Investment Management
New Jersey
-$86.8K -11,556 Closed
YIH
83
Y-Intercept (HK)
Hong Kong
-$79.7K -10,615 Closed
ADL
84
Asset Dedication LLC
California
-$11K -1,463 Closed
MLICM
85
Metropolitan Life Insurance Company (MetLife)
New York
-$9.02K -1,201 Closed
Russell Investments Group
86
Russell Investments Group
United Kingdom
-$2.02K -269 Closed

ALXO Hedge Fund Activity: Q3 2023 in Review

76 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q3 2023, worth a combined $160M — down 38% from $258M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ALXO positions and 10 closed out — a net gain of 2 holders — while 23 added to existing stakes and 22 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $1.21M. The largest seller was Artal Group, exiting entirely with an estimated $3.75M sold.

  • 76 institutional investors held ALX Oncology (ALXO) as of Q3 2023, up from 75 in Q2 2023.
  • Funds reported $160M of ALX Oncology stock for Q3 2023, down 38% quarter-over-quarter.
  • 12 funds opened new ALX Oncology positions in Q3 2023 and 10 closed out, a net change of +2 holders.
  • The largest ALX Oncology buyer in Q3 2023 was Citadel Advisors, an estimated $1.21M added.
  • The largest ALX Oncology seller in Q3 2023 was Artal Group, an estimated $3.75M sold.

Based on aggregated 13F filings for Q3 2023.